



XXXII CONGRESSO NAZIONALE AIRO
XXXIII CONGRESSO NAZIONALE AIRB
XII CONGRESSO NAZIONALE AIRO GIOVANI

AIRO2022

Radioterapia di precisione per un'oncologia innovativa e sostenibile

BOLOGNA, 25-27 NOVEMBRE
PALAZZO DEI CONGRESSI

 Associazione Italiana
Radioterapia e Oncologia clinica

 Società Italiana di Radiobiologia

 Associazione
Italiana
Radioterapia
e Oncologia
clinica


XXXII CONGRESSO NAZIONALE AIRO
XXXIII CONGRESSO NAZIONALE AIRB
XII CONGRESSO NAZIONALE AIRO GIOVANI

AIRO2022

Radioterapia di precisione per un'oncologia innovativa e sostenibile

BOLOGNA, 25-27 NOVEMBRE
PALAZZO DEI CONGRESSI

LA QUALITÀ DI UN PIANO DI CURA IN RADIOTERAPIA STEREOTASSICA Il punto di vista del fisico medico



UNIVERSITÀ
DEGLI STUDI
FIRENZE

DIPARTIMENTO DI
SCIENZE BIOMEDICHE
SPERIMENTALI E CLINICHE

Stefania Pallotta



Azienda
Ospedaliero
Universitaria
Careggi




Associazione Italiana
Radioterapia e Oncologia clinica



Società Italiana di Radiobiologia






DICHIARAZIONE


Relatore: Stefania Pallotta

Come da nuova regolamentazione della Commissione Nazionale per la Formazione Continua del Ministero della Salute, è richiesta la trasparenza delle fonti di finanziamento e dei rapporti con soggetti portatori di interessi commerciali in campo sanitario.

- Posizione di dipendente in aziende con interessi commerciali in campo sanitario **(NIENTE DA DICHIARARE)**
- Consulenza ad aziende con interessi commerciali in campo sanitario **(NIENTE DA DICHIARARE)**
- Fondi per la ricerca da aziende con interessi commerciali in campo sanitario **(NIENTE DA DICHIARARE)**
- Partecipazione ad Advisory Board **(NIENTE DA DICHIARARE)**
- Titolarità di brevetti in compartecipazione ad aziende con interessi commerciali in campo sanitario **(NIENTE DA DICHIARARE)**
- Partecipazioni azionarie in aziende con interessi commerciali in campo sanitario **(NIENTE DA DICHIARARE)**
- Altro



SRT





well localized targets
high Dose
few fractions


Quality = Performance - Expectations

AIRO2022



XXXII CONGRESSO NAZIONALE AIRO
XXXIII CONGRESSO NAZIONALE AIRB
XII CONGRESSO NAZIONALE AIRO GIOVANI

Radioterapia di precisione per un'oncologia innovativa e sostenibile








What is the quality of the planned treatment plan?




AIRO2022


XXXII CONGRESSO NAZIONALE AIRO
XXXIII CONGRESSO NAZIONALE AIRB
XII CONGRESSO NAZIONALE AIRO GIOVANI

Radioterapia di precisione per un'oncologia innovativa e sostenibile






Quantitative metrics




Gradient index

Dose fall-off steepness
outside the target




Homogeneity index


Dose homogeneity in
the target



Conformity index

Dose conformity
to the target





Homogeneity Index

$$HI_T = \frac{D_{max}}{D_{min}}$$

$$HI_{RTOG} = \frac{D_{max}}{D_p}$$


Shaw, et al.. *IJROBP* 1993;27:1231-9

$$HI = \frac{D_2 - D_{98}}{D_p} \times 100$$

Wo, et al.. *IJROBP* 2003;26:573-85.

$$HI = \frac{D_5}{D_{95}}$$

Semerenko, et al. *Med Phys* 2008;35:5851-60.



D_{max} = max dose in the target

D_{min} = min dose in the target

D_p = prescribed dose



D_5 = min dose in 5% of the target

D_2 = min dose in 2% of the target

D_{95} = min dose in 95% of the target


D_{98} = min dose in 98% of the target

Homogeneity Index



$$HI = \frac{OA^2}{IA \times AA}$$



Yan, et al. J Appl Clin Med Phys 2019; 20:11:50–56



Conformity Index

$$CI_{\text{RTOG}} = \frac{PIV}{TV}$$

Shaw, et al.. *IJROBP* 1993;27:1231-9




$$CI_{\text{Paddick}} = \frac{TV_{PIV}^2}{TV \times PIV}$$

Paddick.. *J N* 2000;93:219-222.




PIV = prescription isodose volume 

TV = target volume 


TV_{PIV} = the volume of the target covered by PI




Is the planned treatment the same as the delivered?





Linac beam model
Dose calculation algorithm




linac parameters



TPS Dose calculation accuracy
Linac calibration




Patient Specific Quality Assurance








portal
dosimetry


Measured = Planned





Plan complexity metrics

fluence








Is the planned treatment robust ?



Patient setup - Anatomical changes or movements - Density changes

Robust plan  CTV/ITV receives the prescribed dose
OARs fulfil restrictions




Margins approach  PTV, PRV

But the margin approach presents several limitations!

It relies on the so-called static dose cloud approximation.

It does not guarantee optimal management for PTVs extending into air.



No margins approach




Robust optimization


Instead of optimizing a single scenario, dose distributions are optimized for n possible scenarios.

worst-case scenario

probabilistic approach




It is always possible to make an a posteriori assessment of the plan's robustness.




Conclusions

SRT quality depends on:

Planned plan



Plan complexity



Plan robustness

